Publicaciones en las que colabora con Enrique Navas Elorza (34)

2022

  1. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  2. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  3. Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017)

    Mayo Clinic Proceedings, Vol. 96, Núm. 1, pp. 132-146

  4. Prevention, diagnosis and management of post‐surgical mediastinitis in adults consensus guidelines of the spanish society of cardiovascular infections (Seicav), the spanish society of thoracic and cardiovascular surgery (sectcv) and the biomedical research centre network for respiratory diseases (ciberes)

    Journal of Clinical Medicine, Vol. 10, Núm. 23

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

2019

  1. Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry

    General Thoracic and Cardiovascular Surgery, Vol. 67, Núm. 7, pp. 585-593

  2. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

2018

  1. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis

    Journal of Infection and Chemotherapy, Vol. 24, Núm. 7, pp. 555-562

  2. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse

    Journal of the American College of Cardiology, Vol. 71, Núm. 24, pp. 2731-2740

  3. Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study

    Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832

2017

  1. Infective endocarditis in patients with cancer: A consequence of invasive procedures or a harbinger of neoplasm? A prospective, multicenter cohort

    Medicine (United States), Vol. 96, Núm. 38

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Current epidemiology and outcome of infective endocarditis: A multicenter, prospective, cohort study

    Medicine (United States), Vol. 94, Núm. 43

  2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  3. Left-sided infective endocarditis in patients with liver cirrhosis

    Journal of Infection, Vol. 71, Núm. 6, pp. 627-641

2009

  1. Observational study to evaluate clinical outcomes after first-line efavirenz-or Lopinavir-Ritonavir-based HAART in treatment-naive patients

    Journal of the International Association of Physicians in AIDS Care, Vol. 8, Núm. 5, pp. 308-313

2005

  1. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults

    HIV Clinical Trials, Vol. 6, Núm. 6, pp. 312-319

  2. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors

    Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 5, pp. 800-804

2004

  1. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin

    Antiviral Therapy, Vol. 9, Núm. 1, pp. 133-138